Eli Lilly and Company (NYSE:LLY) Given “Outperform” Rating at Royal Bank Of Canada

Posted by Ethan Ryder on Oct 13th, 2026

Royal Bank Of Canada reiterated their outperform rating on shares of Eli Lilly and Company (NYSE:LLY – Free Report) in a research note issued to investors on Monday, Marketbeat reports. Royal Bank Of Canada currently has a $1,500.00 price target on the stock.

A number of other brokerages have also recently issued reports on LLY. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a report on Thursday, September 17th. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Citigroup raised their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Bank of America lifted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

View Our Latest Stock Report on LLY

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,183.51 on Monday. The stock has a market cap of $1.11 trillion, a price-to-earnings ratio of 39.72, a PEG ratio of 1.47 and a beta of 0.46. The business’s fifty day moving average is $1,175.57 and its 200 day moving average is $1,100.31. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts expect that Eli Lilly and Company will post 36.19 EPS for the current fiscal year.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last three months. 0.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently made changes to their positions in the company. Integrity Financial Corp WA lifted its holdings in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after buying an additional 8 shares during the period. Willner & Heller LLC grew its position in shares of Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after buying an additional 9 shares in the last quarter. Aspiring Ventures LLC increased its stake in shares of Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after buying an additional 9 shares during the period. Wealthspan Partners LLC increased its stake in shares of Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after buying an additional 9 shares during the period. Finally, Navigoe LLC increased its stake in shares of Eli Lilly and Company by 8.7% during the second quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after buying an additional 9 shares during the period. Institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Potentially higher revenue guidance: RBC said Lilly could raise its full-year revenue outlook, citing continued momentum for its diabetes and weight-loss products. Eli Lilly Likely to Raise Revenue Outlook Amid Strong Diabetes, Weight-Loss Drug Sales
Positive Sentiment: Positive analyst view: Royal Bank of Canada reiterated its “Outperform” rating and maintained a $1,500 price target, implying significant upside from the recent trading level. Eli Lilly and Company’s Outperform Rating Reiterated at Royal Bank Of Canada
Positive Sentiment: Encouraging Taltz-Zepbound data: New Phase 3b results showed that combining Taltz with Zepbound produced greater skin clearance and weight loss than standard treatment in adults with plaque psoriasis and obesity. The results may support a broader immunometabolic treatment opportunity for Lilly. Lilly reports Phase IIIb data on Taltz and Zepbound combination
Positive Sentiment: Demand remains visible: Illicit online sales of investigational retatrutide before launch underscore strong interest in Lilly’s next-generation obesity candidate, although the activity also creates counterfeit-drug and regulatory risks. Lilly is fighting a black market for its new obesity drug even before it launches
Neutral Sentiment: Recent pullback viewed as profit-taking: Commentary characterized Lilly’s recent retreat as a normal pause following a strong run rather than evidence that demand for its GLP-1 medicines or the long-term growth thesis has deteriorated. Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.
Negative Sentiment: Combination-treatment risk: Although Taltz plus Zepbound generated more weight loss than Zepbound alone, discontinuation rates were also substantially higher, potentially limiting real-world adoption unless tolerability improves. This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.